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Angiotensin-converting enzyme (ACE) insertion(I)/deletion
(D) polymorphism may modify the effect of inhibition of the
renin–angiotensin–aldosterone system (RAAS) on survival and
cardiorenal outcomes in type 2, diabetes. A consecutive
cohort of 2089 Chinese type 2 diabetic patients with mean
(7standard deviation) age of 59.7713.1 years were
genotyped for this polymorphism by polymerase chain
reaction method and were followed prospectively for a
median period of 44.6 (interquartile range: 23.7, 57.5)
months. Clinical outcomes, including all-cause mortality,
cardiovascular and renal end points, were examined. The
frequency for I allele was 67.1 and 32.9% for D allele, with
observed genotype frequencies of 45.8, 42.6, and 11.6% for 3,
DI and DD, respectively. ACE DD polymorphism was an
independent predictor for renal end point with hazard ratio
(HR) (95% confidence interval) of 1.72 (1.16, 2.56), but not for
cardiovascular end point or mortality. After controlling for
confounding factors, including ACE I/D genotype, the usage
of RAAS inhibitors was associated with reduced risk of
mortality (HR 0.34 (0.23, 0.50)) and renal end point (HR 0.55
(0.40, 0.75)). On subgroup analysis, the beneficial effects on
survival (II vs DI vs DD: HR 0.29 (0.16, 0.51) vs 0.25 (0.14, 0.46)
vs 1.33 (0.41, 4.31)) and renoprotection (II vs DI vs DD: 0.52
(0.30, 0.90) vs 0.43 (0.25, 0.72) vs 0.95 (0.43, 2.12)) were most
evident in II and DI carriers. In conclusion, inhibition of RAAS
was associated with reduced risk of mortality and occurrence
of renal end point in Chinese type 2 diabetic patients. These
benefits were most evident among II and DI carriers.
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Angiotensin-converting enzyme (ACE) is one of the key
enzymes in the renin–angiotensin–aldosterone system
(RAAS). The insertion (I)/deletion (D) polymorphism of
this gene has been studied extensively with respect to its
association with diabetic renal1 and cardiovascular compli-
cations.2 Patients with DD genotype or D allele have elevated
circulating and tissue ACE activity3 compared to patients
with I allele. This may contribute to the interindividual
variability in the antiproteinuric responses to inhibition of
the RAAS using either ACE inhibitor or AII receptor blockers
(ARB).4 Although the beneficial effects of RAAS inhibition
on cardiorenal end points in type 2 diabetic patients have
been confirmed by several landmark studies,5–8 examination
of pharmacogenetics in diabetic nephropathy may improve
our understanding of the heterogeneity of treatment
responses and help identify groups of patients who are most
likely to benefit from the drug as well as develop alternative
hypothesis among nonresponders. In this large-scale ob-
servational study of Chinese type 2 diabetic patients, we
examined the effects of RAAS inhibition on survival and
cardiorenal outcomes in relation to ACE I/D polymorphism
in a consecutive cohort referred to our clinic since 1995.
RESULTS
A total of 2089 (41.4% males, mean age 59.7713.1 years)
patients with median follow-up of 44.6 (23.7, 57.5) months
were enrolled for survival analysis. The frequencies of normo-,
micro- and macroalbuminuria in this prospective cohort were
58.6, 21.2 and 20.2%, respectively. The frequency for I allele
was 67.1 and 32.9% for D allele, with observed geno-
type frequencies of 45.8, 42.6 and 11.6% for II, DI and DD,
respectively. Genotype frequencies were in Hardy–Weinberg
equilibrium. Table 1 summarizes the clinical and biochemical
profiles of patients according to genotypes. They had
comparable age, duration of diabetes and clinical character-
istics, including the albuminuric status. Serum ACE activity
was measured in a random cohort of 718 patients. In this
subgroup, DD carriers (n¼ 75) had higher serum ACE
activity than DI (n¼ 310) and II carriers (n¼ 333)
(61.8720.5 vs 56.6723.0 vs 44.5731.2 U/l, Po0.001). These
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patients had similar clinical characteristics as those in whom
serum ACE activity was not available (data not shown).
RAAS inhibitors were used in 45.6, 42.9, and 40.7% of II,
DI and DD carriers, respectively. The majority of these
patients (84.5%) were treated with an ACE inhibitor. A small
proportion (15.5%) of patients had been treated with an ACE
inhibitor and then switched to an ARB, or treated with an
ARB as initial therapy. None of the patients were on
combination therapy with ACE inhibitor and ARB. Com-
pared to ACE inhibitor users, ARB users had higher systolic
blood pressure (150727 vs 144721 mmHg, P¼ 0.001) and
higher serum creatinine (106 (77, 151) vs 79 (64, 98) mmol/l,
Po0.001).
The usage of RAAS inhibitors was significantly associated
with reduced mortality after controlling for other confound-
ing factors, including ACE I/D genotype (hazard ratio (HR)
0.34 (0.23, 0.50)). Other predicting factors for mortality
included age, duration of diabetes, albumin excretion rate
(AER) and presence of macrovascular complications at
baseline. Although use of RAAS inhibitor was associated
with reduced mortality, ACE I/D genotype was not a
predictor for survival (data not shown). On subgroup
analysis, the beneficial effect of RAAS inhibition on survival
was most evident in II and DI carriers (II vs DI vs DD: HR
0.29 (0.16, 0.51) vs 0.25 (0.14, 0.46) vs 1.33 (0.41, 4.31)).
The cumulative rates of renal end point were 21.6, 34.8
and 36.5% in II, DI and DD carriers, respectively. On
multivariate analysis, after controlling for confounding
factors and compared to patients with II genotype, DD
genotype conferred an approximately two-fold increased risk
of renal end point. In the whole group, RAAS inhibition was
associated with reduced risk of occurrence of renal end point
even controlling for ACE I/D genotype (Table 2, Model 1).
On stratifying patients according to their genotypes and
usage of RAAS inhibitors, the renoprotective effects of RAAS
inhibition were most evident in patients with II and DI
genotypes (Table 2, Model 2). Other predictors for renal end
point include albuminuria, systolic blood pressure, body
mass index, presence of macrovascular, and ophthalmic
complications at baseline. As shown in Figure 1, in the
subgroup of patients treated with RAAS inhibition, DD
carriers had the highest risk of development of composite
renal end point (DD carriers vs II carriers OR 1.84 (95%
confidence interval (CI): 1.11, 3.05)). Table 3 summarizes the
effects of RAAS inhibition on composite renal end points
categorized by baseline albuminuric status and genotype of
Table 1 | Baseline characteristics of 2089 Chinese type 2 diabetic patients categorized according to their ACE I/D polymorphism
genotypes
II (n=956) ID (n=890) DD (n=243) P-value
Age (year) 59.9712.7 59.1713.4 60.7713.0 0.19
Male (%) 43.2 39.9 39.5 0.29
Duration of diabetes (year) 7.176.3 7.076.4 7.176.3 0.92
Family history of diabetes 39.6 38.2 39.1 0.82
Smoking (% current/ex-smoker) 28.9 28.9 27.2 0.85
Systolic BP (mmHg) 137722 135724 136721 0.19
Diastolic BP (mmHg) 80711 79712 80711 0.12
Waist to hip ratio 0.8970.07 0.8870.08 0.8970.06 0.56
Body mass index (kg/m2) 24.973.8 24.973.9 24.873.6 0.97
HbA1c (%) 7.971.9 7.871.9 7.972.0 0.81
Fasting plasma glucose (mmol/l) 8.973.7 8.873.4 9.273.5 0.25
Total cholesterol (mmol/l) 5.571.2 5.571.3 5.571.3 0.69
Triglyceride (mmol/l) 1.39 (0.96, 2.07) 1.36 (0.89, 2.00) 1.32 (0.94, 2.02) 0.43
HDL-C (mmol/l) 1.270.3 1.370.4 1.370.4 0.21
LDL-C (mmol/l) 3.470.9 3.571.1 3.570.9 0.31
Plasma creatinine (mmol/l) 73 (60, 91) 72 (60, 91) 74 (63, 93) 0.30
Estimated GFR (ml/min/1.73 m2) 89.5 (70.6, 109.6) 90.2 (72.1, 107.3) 85.3 (68.5, 101.8) 0.08
4-h albumin excretion rate (mg/min) 19.2 (8.7, 113.0) 18.6 (8.4, 132.1) 16.7 (9.2, 138.4) 0.98
Spot urine albumin:creatinine ratio (mg/mmol) 1.87 (0.68, 13.48) 1.57 (0.60, 10.40) 1.85 (0.73, 15.58) 0.64
Serum ACE activity (U/l)a 44.5731.2 56.6723.0 61.8720.5 o0.001
Renal insufficiency (%)b 15.7 17.9 18.2 0.40
Albuminuric status (%) 0.59
Normoalbuminuric 57.4 59.1 61.8
Microalbuminuric 22.4 20.8 17.6
Macroalbuminuric 20.2 20.0 20.6
Use of antihypertensive treatment (%) 30.1 29.5 34.8 0.56
Use of lipid-lowering treatment (%) 30.2 29.9 32.9 0.62
Presence of cardiovascular complications (%)c 12.7 12.6 16.9 0.18
Presence of retinopathy (%) 32.8 30.5 35.0 0.33
Data are presented as mean7s.d. or median (interquartile range) where appropriate.
aA random sample of 718 patients had serum ACE activity measured and their clinical characteristics were not statistically different from other patients.
bRenal insufficiency was defined as serum creatinine X150 mmol/l and/or eGFR o60 ml/min/1.73 m2.
cCardiovascular complications were defined as the presence of congestive heart failure, ischemic heart disease, revascularization, cerebrovascular accident or peripheral
vascular disease at baseline.
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ACE I/D polymorphism after adjustment of other confound-
ing factors. The renoprotective effect of RAAS inhibitors was
observed in all patients with macroalbuminuria irrespective
of their ACE I/D genotype, with the effects most evident in
the II carriers.
There was a trend for DD carriers to develop more
cardiovascular end points (HR 1.05 (0.69, 1.59)) than II or
DI carriers, albeit short of statistical significance. RAAS
inhibition showed a nonsignificant benefit in reducing
cardiovascular end point in all patients (data not shown).
DISCUSSION
In this relatively large-scale prospective study, we have shown
that both ACE I/D polymorphism and RAAS inhibition were
independent predictors for renal end points in Chinese type 2
diabetic patients. Somewhat counter-intuitively but in
agreement with previous studies,9 the benefit of RAAS
inhibition on reducing the risk of mortality and renal end
point was most evident among II and DI carriers.
Diabetic nephropathy is a major cause of morbidity and
mortality, especially in non-Caucasian populations.10 Both
clinical and animal studies have suggested that intrarenal
angiotensin II (Ang II) plays a pivotal role in the
development of nephropathy. In this connection, blocking
of RAAS by ACE inhibitors or ARB has been shown to delay
the progression of nephropathy.5,7 The ACE I/D polymorph-
ism accounts for over 40% of interindividual variability of
serum or tissue ACE activity,11 and its association with
diabetic nephropathy has been extensively investigated.1,12,13
In addition to modifying the metabolic profile, albuminuria,
and blood pressure, which collectively account for one-third
of the variability of diabetic nephropathy,14 ACE I/D
polymorphism is a potential modulating factor in the
progression of nephropathy in both type 1 and type 2
diabetic patients.15–17
Apart from having higher serum ACE activity, D allele
carriers had similar baseline characteristics as the non-D
carriers. However, on prospective analysis, ACE DD genotype
was associated with two-fold increased risk of occurrence of
renal event, but not for death or cardiovascular events. After
controlling for conventional risk factors, including blood
pressure, duration of disease, albuminuria, and diabetic
complications, RAAS inhibition reduced the risk of occur-
rence of renal end point by 45% (Table 2) and death by 66%.
On subgroup analysis after stratification by ACE D/I
genotype and albuminuric status, the renoprotective effects
Table 2 | Multivariate analysis using Cox regression model,
showing the HRs (95% CIs) of various predictors for
composite renal end point in 2089 Chinese type 2 diabetic
patientsa
Variable HR (95% CI) P-value
Model 1b
Ln 4-h albumin excretion rate (mg/min) 1.92 (1.77, 2.09) o0.001
Systolic blood pressure (mmHg) 1.01 (1.00, 1.02) 0.006
Body mass index (kg/m2) 0.92 (0.89, 0.97) 0.001
Presence of macrovascular complications 1.77 (1.27, 2.45) 0.0007
Presence of ophthalmic complications 2.33 (1.64, 3.30) o0.001
ACE I/D polymorphismc
DI carriers 1.20 (0.89, 1.62) 0.22
DD carriers 1.72 (1.16, 2.56) 0.007
Usage of RAAS inhibition 0.55 (0.40, 0.75) 0.0002
Model 2
Ln 4-h albumin excretion rate (mg/min) 1.92 (1.77, 2.09) o0.001
Systolic blood pressure (mmHg) 1.01 (1.00, 1.02) 0.006
Body mass index (kg/m2) 0.92 (0.89, 0.97) 0.001
Presence of macrovascular complications 1.77 (1.27, 2.45) 0.0007
Presence of ophthalmic complications 2.33 (1.64, 3.30) o0.001
ACE I/D polymorphism 0.03
Usage of RAAS inhibition
Usage of RAAS inhibitor and II genotype 0.52 (0.30, 0.90) 0.02
Usage of RAAS inhibitor and DI genotype 0.43 (0.25, 0.72) 0.001
Usage of RAAS inhibitor and DD genotype 0.95 (0.43, 2.12) 0.91
Other independent variables, including age, male sex, duration of diabetes, baseline
HbA1c and total cholesterol, were not selected in the model.
aTime to event analyses using Cox regression to calculate the risk of occurrence of
renal end point expressed as HR with 95% CI. Renal end point was defined as death
due to renal failure, dialysis, eGFR o15 ml/min/1.73m2 or more than 50% loss of
eGFR compared with baseline using the Modification of Diet in Renal Disease
equation.
bModel 1 estimated the risk association of ACE I/D polymorphism and renal end
point after adjustment for other confounding factors, including usage of RAAS
inhibition. Model 2 estimated the renoprotective effect of RAAS inhibition with
respect to ACE I/D polymorphism after adjustment for other confounding factors.
cIn estimating the risk association of ACE I/D polymorphism and renal end point,
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Figure 1 | Cumulative renal events in Chinese type 2 diabetic
patients categorized according to ACE I/D genotype, who were
treated with RAAS inhibitors (n¼ 917).
Table 3 | The impact of renin–angiotensin–aldosterone-system
inhibition on risk of occurrence of renal end point in 2089
Chinese type 2 diabetic patients stratified by their ACE I/D
genotype and baseline albuminuric status
II DI DD
Macroalbuminuric 0.25 (0.15, 0.42) 0.31 (0.18, 0.53) 0.40 (0.17, 0.94)
Microalbuminuric 1.40 (0.39, 4.97) 1.15 (0.38, 3.51) 1.95 (0.22, 17.48)
Normoalbuminuric NA 1.99 (0.44, 9.03) 1.26 (0.23, 6.92)
Time to event analyses using Cox regression were performed to calculate the risk of
renal events stratified by both ACE I/D polymorphism and baseline albuminuric
status, expressed as HR (95% CI).
Renal end point was defined as death due to renal failure, dialysis, eGFR ofo15 ml/
min/1.73 m2 or more than 50% loss of eGFR compared with baseline using the
Modification of Diet in Renal Disease equation.
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of RAAS inhibition were most evident in the II and DI
carriers (Table 2). Similarly, the effect of RAAS inhibition on
mortality was also mainly observed in these two groups.
When looked at another way, while RAAS inhibition
conferred renoprotection in all patients with macroalbumi-
nuria, the effects were most evident among the II carriers
(Table 3). Although these results may be due to the small
number of patients with DD genotype, they are consistent
with findings from other long-term studies, which also
indicated that the antiproteinuric response to ACE inhibition
in patients with diabetic nephropathy was attenuated among
the DD carriers.9,18
Our study cohort was recruited between 1995 and 2000, a
time before publication of several landmark studies such as
RENAAL, IDNT and LIFE.6–8 Hence, most of the patients
were treated with ACE inhibitors rather than ARB (n¼ 323).
In this regard, ACE inhibitor reduces the conversion from
Ang I to Ang II, which is accompanied by increased renin and
Ang I levels, both of which can result in resistance to ACE
inhibition over time.19 Besides, in both diabetes and
hypertension, there is evidence of upregulation of alternative
pathways for Ang II production, such as the chymase-
mediated activity, which can escape ACE inhibition. In
support of this notion, ACE expression within diabetic
kidneys does not appear to correlate with degree of
glomerulosclerosis and proteinuria.20 Taken together, it is
plausible that combination treatment of ACE inhibitor and
ARB may offer more complete blockade of the RAAS and
thus reduction of intrarenal Ang II production.21,22 Indeed,
in nondiabetic patients with renal insufficiency, dual
blockade of ACE inhibitor and ARB has been shown to be
more effective than single therapy of either drug in reducing
renal end point.23 However, similar studies in type 2 diabetes,
which is the main contributor to the growing burden of renal
disease, are still awaited.
Subjects in our study were not randomized with regard to
ACE inhibition, and this may have resulted in selection bias.
Other confounding factors, such as changes in antihyperten-
sive therapy or changes in blood pressure, obesity, dyslipi-
demia, and glycaemic control during the observational
period, can influence the progression of nephropathy.
Survival bias with certain genotypes may be confounding
due to possible association between D allele and premature
death from cardiovascular events.13 However, the genotype
distribution in our cohort was in Hardy–Weinberg equili-
brium and the association between cardiovascular outcome
and ACE I/D polymorphism was insignificant, suggesting
that there should be minimal dropout. We were also not able
to specifically examine the effect of ARB in different ACE I/D
genotype carriers due to the relatively small number of
subjects treated with ARB.
In conclusion, we have observed the potential interaction
between ACE I/D polymorphism and RAAS inhibition in
Chinese type 2 diabetic patients. After controlling for
conventional risk factors, ACE DD genotype remained an
independent predictor for occurrence of renal end point.
While RAAS inhibition was associated with improved
survival and renoprotection, these beneficial effects were
most evident among the II and DI carriers. Given the high
renal risk of patients with DD genotype and their less
favorable response to RAAS inhibition, there is a need to




The Prince of Wales Hospital is the teaching hospital of the Chinese
University of Hong Kong. It serves a population of over 1.2 million.
Between 1995 and 2001, a consecutive cohort of 5205 Chinese type 2
diabetic patients from the hospital underwent detailed assessment
using the European DiabCare protocol.24 We have previously
reported the prognostic effects of albuminuria in a subgroup of
3773 patients on renal outcome.25 Among these patients, 1281 had
genotyping for ACE I/D polymorphism, which was found to predict
the renal outcome.26 In this analysis, we have performed additional
genotyping to increase the latter cohort size to 2089 subjects
recruited consecutively from 1995 to 1998 in whom detailed
documentation of drug information was also available. Patients
with type 1 diabetes, defined as presentation with diabetic
ketoacidosis, acute symptoms with heavy ketonuria (43þ ) or
continuous requirement of insulin within 1 year of diagnosis27 were
excluded.
Apart from documentation of demographic data and clinical
assessment of diabetic complications, fasting blood samples were
taken for measurement of plasma glucose, glycated hemoglobin
(HbA1c), lipid profile (total cholesterol (TC), high-density lipo-
protein-cholesterol (HDL-C), and triglycerides (TG), calculated low-
density lipoprotein-cholesterol (LDL-C), renal and liver functions. All
patients had at least two urinary collections: a sterile, random spot
urine sample was used to measure albumin creatinine ratio (ACR),
followed by a timed collection (4 or 24 h) for measurement of ACR
and AER. None of the patients had known history of glomerulone-
phritis, microscopic hematuria or known history of obstructive
uropathy, such as renal stone on ultrasound scan. Definition of
albuminuria was based on the mean value of ACR from both the
timed and spot urinary samples. Normoalbuminuria was defined as a
mean ACRp3.5 mg/mmol, microalbuminuria ACR between 3.5 and
25 mg/mmol and macroalbuminuria X25 mg/mmol.28
In this prospective analysis, mortality data were obtained from
the Hong Kong Death Registry and further ascertained by review of
case notes. Details of all medical admissions with primary and
secondary diagnosis, as well as medication history and last available
plasma creatinine results, were retrieved from the Central Compu-
terized System at the Hospital Authority Head Office. The latter is
the governing body of all public hospitals in Hong Kong and
captures more than 90% of these data. Cardiovascular end point was
defined as hospitalizations due to ischemic heart disease, congestive
heart failure, stroke and revascularization procedures. Renal end
point was defined as death due to renal failure, dialysis, estimated
glomerular filtration rate (eGFR) of less than 15 ml/min/1.73 m2 and/
or more than 50% loss of glomerular filtration rate compared with
baseline using the Modification of Diet in Renal Disease equation.29
Laboratory assays
Plasma glucose was measured by a hexokinase method (Hitachi 911
automated analyzer, Boerhringer Mannheim, Mannheim, Germany).
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HbA1c was measured by an automated ion-exchange chromato-
graphic method (Bio-Rad Laboratory, Hercules, CA, USA with
reference range: 5.1–6.4%). Inter- and intra-assay coefficient of
variation (CV) for HbA1c wasp3.1% at values below 6.5%. TC, TG
and HDL-C were measured by enzymatic methods on a Hitachi 911
automated analyzer (Boehringer, Mannheim, Germany) using
reagent kits supplied by the manufacturer of the analyzer. LDL-C
was calculated by the Friedewald’s equation for TG o4.5 mmol/l.30
The precision performance of these assays was within the
manufacturer’s specifications. Urinary creatinine (Jaffe’s kinetic
method) and albumin (immunoturbidimetry method) were also
measured by the Hitachi 911 analyzer using reagent kits supplied by
the manufacturer. The inter-assay precision CV was 12.0 and 2.3%
for urinary albumin concentrations of 8.0 and 68.8 mg/l, respec-
tively. The lowest detection limit was 3.0 mg/l. Plasma creatinine
(Jaffe’s kinetic method) was measured on a Dimension AR system
(Dade Behring, Deerfield, IL, USA).
Genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes.
Genotyping for the ACE gene I/D polymorphism was performed
using the polymerase chain reaction (PCR) method as described
previously.31 PCR amplification revealed a 490-bp product (I allele)
and/or 190-bp product (D allele) depending on the presence or
absence of the insertion of a 278-bp fragment.
Data analysis
The analysis was performed using the Statistical Package for Social
Sciences (version 9.0) statistical package. Plasma TG, plasma
creatinine and albuminuria were logarithmically transformed due
to skewed distributions. All data are expressed as mean7standard
deviation or median (interquartile range), as appropriate. The
Student’s t-test or analysis of variance was used for between-group
comparisons for continuous variables and w2 test for categorical
variables. Cox-regression model was used to estimate the HR with
95% CI for mortality and clinical end points, with the assumption
that the effects of the different variables on survival are constant.
Independent variables were subjected to univariate analysis and then
variables showing statistically significant results were entered as
covariates in the multivariate analysis. Kaplan–Meier analysis was
used to estimate the cumulative incidence of death and cardiorenal
outcomes, and log rank test was used to demonstrate the trend for
survival. A P-value o0.05 (two-tailed) was considered to be
significant.
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